The Federal Court of Appeal made it clear that the disclosure of a patent should always be taken into consideration when interpreting its claims, not just when a claim term is unclear. The Court emphasized that the objective intention of the inventors is to be interpreted through claim construction. As a result, even if words in a claim seem straightforward and unambiguous, the disclosure should be examined to see if the inventor has given them a different definition.

Biogen Canada Inc. v. Pharmascience Inc., 2022 FCA 143

Related